
A COVID-19 vaccine being developed by Daiichi Sankyo Co.
14:04 JST, January 14, 2023
TOKYO — Daiichi Sankyo Co. said Friday it has applied for health ministry approval for a COVID-19 vaccine it is developing, becoming the second Japanese company to do this, after Shionogi & Co.
Daiichi Sankyo assumes that its messenger RNA vaccine, the same kind as ones developed by U.S. makers Pfizer Inc. and Moderna Inc., will be used for booster shots in Japan.
If its vaccine is put into practical use, Daiichi Sankyo would be the first Japanese maker to offer such a vaccine.
The Daiichi Sankyo vaccine has been confirmed as effective in clinical tests with some 5,000 adults who had completed their second inoculations with existing vaccines, including elderly people.
The vaccine boosted neutralizing antibodies in recipients’ bodies more than the Pfizer and Moderna vaccines do, according to Daiichi Sankyo.
The vaccine is designed against early coronavirus variants. Daiichi Sankyo is also developing a bivalent mRNA vaccine that can also combat the omicron variant, with a view to applying for approval by the end of March 2024.
"Business" POPULAR ARTICLE
-
Japan’s Agriculture Ministry Starts Survey of Rice Farmers Across Japan on Production Outlook
-
Japan Eyes Hosting Major International Standards Conference in 2029; Govt Making Plans to Host IEC Event in Yokohama
-
Agriculture Minister Considers Review of Japan’s Rice Harvest Statistics (UPDATE 1)
-
Japan’s Core Inflation Hits 2-year High, Keeps Rate-Hike Bets Alive
-
Carmakers’ Anxiety Grows as U.S. Tariff Talks Stall;Japan Exporters May Have No Choice But to Raise Prices
JN ACCESS RANKING
-
Japan’s Agriculture Ministry Starts Survey of Rice Farmers Across Japan on Production Outlook
-
Japan Eyes Hosting Major International Standards Conference in 2029; Govt Making Plans to Host IEC Event in Yokohama
-
Agriculture Minister Considers Review of Japan’s Rice Harvest Statistics (UPDATE 1)
-
Japan’s Core Inflation Hits 2-year High, Keeps Rate-Hike Bets Alive
-
Carmakers’ Anxiety Grows as U.S. Tariff Talks Stall;Japan Exporters May Have No Choice But to Raise Prices